Allogeneic Stem Cell Transplantation with a Novel Reduced Intensity Conditioning Regimen for the Treatment of Patients with Primary Cutaneous T-cell Lymphomas

Authors

Maria Stamouli¹, Konstantinos Gkirkas¹, Aggeliki Karagiannidi¹, Theodoros Iliakis², Spiros Chondropoulos¹, Thomas Thomopoulos¹, Vassiliki Nikolaou³, Vassiliki Pappa¹, Evangelia Papadavid⁴, Panagiotis Tsirigotis^{1, *,}

¹Hematology Division, 2nd Department of Internal Medicine, Propaedeutic, ATTIKON General University Hospital, National and Kapodistrian University of Athens, Greece

²Hematology Division, 1st Department of Internal Medicine, Propaedeutic, LAIKON General Hospital, National and Kapodistrian University of Athens, Greece

³1st Department of Dermatology, Syggros Hospital, National and Kapodistrian University of Athens, Greece

⁴2nd Department of Dermatology, ATTIKON General University Hospital, National and Kapodistrian University of Athens, Greece

^*Corresponding author. Email: panagtsirigotis@gmail.com

DOI

10.2991/chi.k.210529.001How to use a DOI?

Keywords

Mycosis fungoides; sezary syndrome; cutaneous t-cell lymphomas; donor lymphocyte infusion; allogeneic stem cell transplantation; graft-versus-host disease; graft versus lymphoma

Abstract

The prognosis of patients with mycosis fungoides (MF) and Sezary Syndrome (SS) varies greatly, from near normal life expectancy in patients with early stage, to a median survival of less than 2 years for those diagnosed with advanced stage disease. Initial response to treatment is almost always followed by relapse and, finally, most of patients enter a phase of advanced multi-drug resistant disease with a short life expectancy after multiple lines of treatment. Allogeneic stem cell transplantation (allo-SCT) is usually limited to patients with advanced disease resistant to multiple treatments. Retrospective registry-based studies have shown increased Non-relapse Mortality (NRM) rates in patients with poor performance status, as well as in patients treated with myeloablative conditioning regimens. Another major limitation of allo-SCT is the increased relapse rate which occurs in nearly 50% of the cases, and is probably due to the fact that only heavily pretreated patients with advanced disease are referred for allo-SCT. Due to the paucity of data, the ideal conditioning regimen which will provide the maximum therapeutic benefit without the cost of increased NRM is not currently known. In this article we present our experience with a novel regimen in the treatment of patients with advanced MF/SS.

Copyright

© 2021 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.

Open Access

This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Download article (PDF)
View full text (HTML)

TY  - JOUR
AU  - Maria Stamouli
AU  - Konstantinos Gkirkas
AU  - Aggeliki Karagiannidi
AU  - Theodoros Iliakis
AU  - Spiros Chondropoulos
AU  - Thomas Thomopoulos
AU  - Vassiliki Nikolaou
AU  - Vassiliki Pappa
AU  - Evangelia Papadavid
AU  - Panagiotis Tsirigotis
PY  - 2021
DA  - 2021/06/12
TI  - Allogeneic Stem Cell Transplantation with a Novel Reduced Intensity Conditioning Regimen for the Treatment of Patients with Primary Cutaneous T-cell Lymphomas
JO  - Clinical Hematology International
SP  - 72
EP  - 76
VL  - 3
IS  - 2
SN  - 2590-0048
UR  - https://doi.org/10.2991/chi.k.210529.001
DO  - 10.2991/chi.k.210529.001
ID  - Stamouli2021
ER  -